Whitelab Genomics

Whitelab Genomics is a biotechnology company that has developed an AI-powered platform to accelerate the discovery and development of genomic medicines, such as gene and cell therapies. Founded in 2019 by CEO David Del Bourgo, CSO Julien Cottineau, and Lucia Cinque, the company is headquartered in Paris, with a U.S. presence in Cambridge, Massachusetts. The founders established the company after recognizing the potential for data science and AI to systematically improve the lengthy and costly process of developing genomic therapies. Del Bourgo has a background in biomedical engineering, with extensive experience in business development and marketing at companies like GE Healthcare and Genomic Vision. Cottineau is an expert in genomics drug development.

Whitelab Genomics' core offering is its proprietary AI platform, Catalyst™, which is available in a SaaS model. This platform leverages AI and advanced computational methods to analyze complex biological data, allowing for in-silico simulations to discover and design optimized therapeutic candidates. The technology enables the rapid exploration of numerous hypotheses simultaneously, predicting the most effective molecular designs for therapies targeting diseases like cancer and genetic disorders such as cystic fibrosis and Parkinson's. By using this computational approach, the company aims to reduce drug development timelines, mitigate risks, and lower costs associated with bringing new treatments to market. The platform assists in designing both the genetic payload and the delivery vector, critical components of gene therapies.

The company's business model is centered on collaborating with pharmaceutical companies, academic institutions, and biotechnology firms. Its client base includes organizations in Europe and the U.S. that are developing RNA, DNA, and cell-based therapies. Notable partners include Sanofi, Genethon, and Siren Biotechnology. In 2022, Whitelab Genomics was part of the Y-Combinator accelerator program and secured $10 million in a Series A funding round co-led by Omnes Capital and Debiopharm. This funding is intended to support further platform development, team expansion, and international growth, particularly in the U.S.

Keywords: genomic medicine, AI drug discovery, cell therapy, gene therapy, in-silico simulation, computational biology, DNA therapies, RNA therapies, bioproduction, AAV immuno-gene therapy, drug development platform, therapeutic design, vector design, payload design, preclinical development, TechBio, lentiviral vectors, genetic medicine AI, biotherapeutics, drug target discovery